Relation Between Infarct Size in ST-Segment Elevation Myocardial Infarction Treated Successfully by Percutaneous Coronary Intervention and Left Ventricular Ejection Fraction Three Months After the Infarct

2010 ◽  
Vol 106 (5) ◽  
pp. 635-640 ◽  
Author(s):  
Yuri B. Pride ◽  
Jennifer L. Giuseffi ◽  
Satishkumar Mohanavelu ◽  
Caitlin J. Harrigan ◽  
Warren J. Manning ◽  
...  
Author(s):  
Feng Xie ◽  
Lijun Qian ◽  
Andrew Goldsweig ◽  
Di Xu ◽  
Thomas R. Porter

Background: Although small trials have detected microvascular obstruction (MVO) with variable frequency following restoration of epicardial blood flow, the independent impact of abnormal microvascular perfusion (MVP) in predicting patient outcome following emergent percutaneous coronary intervention in acute ST-segment–elevation myocardial infarction is unknown. The study aims to determine the impact of abnormal MVP following successful epicardial recanalization in ST-segment–elevation myocardial infarction. Methods: MVP was analyzed by low mechanical index ultrasound imaging within 48 hours of emergent percutaneous coronary intervention in 297 patients with acute ST-segment–elevation myocardial infarction who had restoration of Thrombolysis in Myocardial Infarction grade 3 flow in the infarct vessel. Patients were divided into normal segmental replenishment (normal MVP) after high mechanical index impulses versus delayed replenishment but normal plateau intensity (delayed MVP) and both delayed replenishment and reduced plateau intensity (MVO by definition). Demographic variables, left ventricular ejection fraction change, and 5-year follow-up of death, recurrent myocardial infarction, and congestive heart failure were analyzed. Results: MVO was seen in 115 patients (39%), delayed MVP in 124 (42%), and normal MVP in 58 patients (19%). Patients with MVO had significant lower left ventricular ejection fraction change (39±12%) at hospital discharge compared with delayed MVP (50±10%; P =0.003) and normal MVP (57±8%; P <0.0001) groups. The MVO group also did not have an improvement in left ventricular ejection fraction change at 3-month follow-up (36±12% versus 37±13%; P =0.18). Both delayed MVP and MVO were independent predictors of adverse events at follow-up (hazard ratio, 21 [CI, 4–116]; P =0.001 and hazard ratio, 30 [CI, 5–183]; P <0.0001, respectively). Conclusions: Reduced or absent MVP following successful percutaneous coronary intervention in acute ST-segment–elevation myocardial infarction is common and associated with significantly worse outcome even with Thrombolysis in Myocardial Infarction 3 flow in the infarct vessel.


2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Byung Gyu Kim ◽  
Sung Woo Cho ◽  
Jeong-Ha Ha ◽  
Hyo Seung Ahn ◽  
Hye Young Lee ◽  
...  

Objectives. Incomplete ST-segment elevation resolution (STR) occasionally occurs despite successful revascularization of epicardial coronary artery after primary percutaneous coronary intervention (PPCI). The aim of this study was to evaluate the relationship between the degree of STR and the severity of microvascular dysfunction. Methods. A total of 73 consecutive patients with ST-segment elevation myocardial infarction (STEMI) who underwent successful PPCI were evaluated. Serial 12-lead electrocardiography was performed at baseline and at 90 minutes after PPCI. Microvascular dysfunction was assessed by index of microvascular resistance (IMR) immediately after PPCI. Results. Patients were classified into 2 groups: 50 patients with complete STR (STR ≥50%) and 23 patients with incomplete STR (STR <50%). The incomplete STR group had a higher IMR value and lower left ventricular ejection fraction (LVEF), compared with the complete STR group. The degree of STR was significantly correlated with IMR (r = −0.416, P=0.002) and LVEF (r = 0.300, P=0.011). These correlations were only observed in patients with left anterior descending artery (LAD) infarction but not observed in patients with non-LAD infarction. A cutoff IMR value was 27.3 for predicting incomplete STR after PPCI. Conclusion. Incomplete STR after PPCI in patients with STEMI reflects the presence of microvascular and left ventricular dysfunction, especially in patients with LAD infarction.


Author(s):  
Rodolfo P Lustosa ◽  
Federico Fortuni ◽  
Pieter van der Bijl ◽  
Laurien Goedemans ◽  
Mohammed El Mahdiui ◽  
...  

Abstract Aims Adverse left ventricular (LV) remodelling after ST-segment elevation myocardial infarction (STEMI) is associated with poor outcome. Global and regional LV myocardial work (LVMW) derived from speckle tracking echocardiographic strain data in combination with non-invasive blood pressure recordings could provide information for prediction of LV remodelling after STEMI. The aim of the study was to assess the predictive value of global and regional LVMW for LV remodelling before discharge in patients with STEMI. Methods and results Three-hundred and fifty STEMI patients treated with primary percutaneous coronary intervention (PCI) were included [265 men (76%), mean age: 61 ± 10 years]. Clinical variables, conventional echocardiographic parameters, global and regional measures of myocardial work index (MWI), and myocardial work efficiency were recorded before discharge. The primary endpoint was early LV remodelling defined as increase in LV end-diastolic volume (LVEDV) ≥20% at 3 months after STEMI. Eighty-seven patients (25%) showed early LV remodelling. The global and regional LVMW in the culprit territory were significantly lower in patients with early LV remodelling. Peak troponin I (OR 1.109, 95% CI 1.046–1.177; P = 0.001), LVEDV (OR 0.972, 95% CI 0.959–0.984; P &lt; 0.001) and regional MWI in the culprit vessel territory (OR 0.602, 95% CI 0.383–0.945; P = 0.027) were independently associated with early LV remodelling. Conclusion In STEMI patients treated with primary PCI and optimal medical therapy, the regional cardiac work index in the culprit vessel territory before discharge is independently associated with early adverse LV remodelling.


2019 ◽  
Vol 9 (5) ◽  
pp. 469-477 ◽  
Author(s):  
Niels PG Hoedemaker ◽  
Vincent Roolvink ◽  
Robbert J de Winter ◽  
Niels van Royen ◽  
Valentin Fuster ◽  
...  

Background: Conflicting evidence is available on the efficacy and safety of early intravenous beta-blockers before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. We performed a patient-pooled meta-analysis of trials comparing early intravenous beta-blockers with placebo or routine care in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Aim: The aim of this study was to evaluate the clinical and safety outcomes of intravenous beta-blockers in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Methods: Four randomized trials with a total of 1150 patients were included. The main outcome was one-year death or myocardial infarction. Secondary outcomes included biomarker-based infarct size, left ventricular ejection fraction during follow-up, ventricular tachycardia, and a composite safety outcome (cardiogenic shock, symptomatic bradycardia, or hypotension) during hospitalization. Results: One-year death or myocardial infarction was similar among beta-blocker (4.2%) and control patients (4.4%) (hazard ratio: 0.96 (95% confidence interval: 0.53–1.75, p=0.90, I2=0%). No difference was observed in biomarker-based infarct size. One-month left ventricular ejection fraction was similar, but left ventricular ejection fraction at six months was significantly higher in patients treated with early intravenous beta-blockade (52.8% versus 50.0% in the control group, p=0.03). No difference was observed in the composite safety outcome or ventricular tachycardia during hospitalization. Conclusion: In ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention, the administration of early intravenous beta-blockers was safe. However, there was no difference in the main outcome of one-year death or myocardial infarction with early intravenous beta-blockers. A larger clinical trial is warranted to confirm the definitive efficacy of early intravenous beta-blockers.


Sign in / Sign up

Export Citation Format

Share Document